RecruitingPhase 3NCT06963021
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Sponsor: Neurocrine Biosciences
Cromwell, CT · Farmington, CT · +13 more sites